Epigenetics in Precision Medicine

Jose Luis Garcia-Gimenez

2021-11 · Translational Epigenetics 30 knyga · Elsevier

El. knyga

614

Puslapiai

Tinkama

Įvertinimai ir apžvalgos nepatvirtinti. Sužinokite daugiau

Apie šią el. knygą

In recent years, knowledge of epigenetic mechanisms underlying disease onset and progression has proven crucial for the development of novel early diagnosis and prognosis biomarkers for patient stratification and precision medicine. Epigenetics in Precision Medicine, a new volume in the Translational Epigenetics series, provides a thorough discussion and overview of current developments in clinical epigenetics with special emphasis on epigenetic biomarkers that can be used for clinical diagnosis, prognosis, patient stratification, and treatment monitoring. Disease types discussed include cancer, metabolic disorders, neurodegenerative diseases, bone disease, and immune-related disorders. The book examines the challenges of advancing epigenetics research and translating findings to the clinic and drug discovery in each of these areas, as well as current solutions; chapter authors discuss how to leverage epigenomic technologies, applications, and tools, such as next-generation sequencing, to discover new epigenetic biomarkers in disease and drug studies. Epigenetics in Precision Medicine focuses on complex epigenetic mechanisms in several pathologies, and explores how epigenetics can power the advance of precision medicine, not only by improving in vitro diagnostic and prognostic tools, but by providing new therapeutic approaches to treat human disease. - Provides a thorough grounding in epigenetics-driven precision medicine, with emphasis on developing and implementing early diagnosis and prognosis biomarkers, and supporting patient stratification - Empowers researchers and clinicians to incorporate epigenetics in new disease research, drug discovery, and clinical practice - Features chapter contributions from international leaders in the field

Apie autorių

Dr. Garcia-Gimenez is a Senior Researcher at the Consortium Center for Biomedical Network Research, the Spanish Institute of Health Carlos III (ISCIII), and the INCLIVA Biomedical Research Institute, in the Dept. of Physiology at the Medicine and Dentistry School at the University of Valencia, Spain. Dr. García-Giménez is founder and CEO of EpiDisease S.L. (Spin-Off of CIBER-ISCIII), which develops the technology based on the patent EP15382319.0, currently in national phases (USTPO, EPO, CIPO and SIPO). EpiDisease received NEOTEC funds from CDTI and the Seal of Excellence from the European Commission in the SME Instrument Phase II H2020. Dr. García-Giménez has received 7 scientific and entrepreneurship national and international awards, including the National Award for Young Entrepreneurs in 2013 (awarded by the Spanish Ministry of Health) and the European Young Researcher from the Free Radical Research Society in 2009 and more recently the Eureka Innovation and Entrepreneurship Award in Melbourne (Australia). Dr. Garcia-Gimenez is a researcher at the University of Valencia. He is early in his career, but has been noticed as an up-and-coming authority in epigenetic biomarker research as it relates to disease, stress, and exercise.

Įvertinti šią el. knygą

Pasidalykite savo nuomone.

Skaitymo informacija

Išmanieji telefonai ir planšetiniai kompiuteriai

Įdiekite „Google Play“ knygų programą, skirtą „Android“ ir „iPad“ / „iPhone“. Ji automatiškai susinchronizuojama su paskyra ir jūs galite skaityti tiek prisijungę, tiek neprisijungę, kad ir kur būtumėte.

Nešiojamieji ir staliniai kompiuteriai

Galite klausyti garsinių knygų, įsigytų sistemoje „Google Play“ naudojant kompiuterio žiniatinklio naršyklę.

El. knygų skaitytuvai ir kiti įrenginiai

Jei norite skaityti el. skaitytuvuose, pvz., „Kobo eReader“, turite atsisiųsti failą ir perkelti jį į įrenginį. Kad perkeltumėte failus į palaikomus el. skaitytuvus, vadovaukitės išsamiomis pagalbos centro instrukcijomis.

Pranešti apie neteisėtą turinį